Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate

Abstract

Skin changes are the most common non-hematologic side effects to IM treatment and are usually dose dependent. In particular, patients with IM therapy reported a lightening and depigmentation of the skin, that may alter the skin protection against ultraviolet exposure, with a possible subsequent intolerance to sun exposure, as reported in our patient, and higher risk of skin cancer. They are frequently self-limited or easily managed; nevertheless, in some cases, the therapy needs to be discontinued or may only be continued with concomitant oral steroid.

Chemotherapy: oral side effects and dental interventions. A review of the literature

“…These histologic features are absent in OLP. [56] LRs usually are caused by several chemicals (e.g. amalgam) or by certain types of medications including chemotherapeutic agents [ Figure 4].…”

“…It impairs CD117, c-kit, or platelet derived tyrosine kinases. [56] Imatinib administration can be accompanied by several side effects, such as periorbital edema, Steven-Johnson syndrome, pityriasis rosea, erythroderma, myalgia, diarrhea, exfoliative dermatitis, or edema of the legs. [57] It is responsible for lichenoid lesions in the oral mucosa, skin, or nails.…”

“…[57] It is responsible for lichenoid lesions in the oral mucosa, skin, or nails. [55,56,58] Suggestions have been expressed concerning the pathogenesis of LRs and LRs relationship with chemotherapy. Imatinib is responsible for the altered expression of epidermal markers.…”

“…All these can justify the hypothesis that the lichenoid reaction lesions may be related to altered expression of epidermal markers because of the imatinib. [56] The management of LRs requires the discontinuation of the causative agent. If the agent cannot be substituted or stopped, corticosteroids can be used.…”

Mechanistic Studies on the Phototoxicity of Rosuvastatin, Itraconazole and Imatinib

“…They include increased photosensitivity [66,71,72], photoinduced dermatitis [72], pseudoporphyria [68,69,73], or squamous cell carcinoma [74]. The occurrence of these adverse effects only in long-term treated patients suggests that the cumulative dosage is determinant for photosensitization [71].…”